Table 1 Size, PDI, ZP, EE% and DL% w/w for the different lipid: surfactant, drug: lipid, and lipid: polymer mass ratios used in the optimization of VCM-HNLCs. Results represented as mean ± SD (n = 3)
Optimization parameter | Size (nm) | PDI | ZP (mV) | EE % | DL % w/w |
|---|---|---|---|---|---|
Lipid: surfactant mass ratio | Fixed drug: lipid (1:4) and lipid: polymer (1:0.1) mass ratios | ||||
 1:0.5 | 98.77 ± 0.436 | 0.156 ± 0.008 | − 2.92 ± 0.332 | 56.18 ± 3.395 | 7.36 ± 1.582 |
 1:1 | 62.29 ± 0.440 | 0.204 ± 0.007 | − 5.41 ± 0.643 | 35.70 ± 0.375 | 5.07 ± 0.052 |
 1:2 | 42.44 ± 1.148 | 0.233 ± 0.005 | − 2.69 ± 0.283 | 20.78 ± 0.934 | 2.07 ± 0.093 |
Drug:lipid mass ratio | Fixed lipid: surfactant (1:0.5) and lipid: polymer (1:0.1) mass ratios | ||||
 1:3 | 90.94 ± 0.0291 | 0.151 ± 0.011 | − 5.59 ± 1.28 | 45.50 ± 0.024 | 5.26 ± 0.006 |
 1:4 | 98.77 ± 0.436 | 0.156 ± 0.008 | − 2.92 ± 0.332 | 56.18 ± 3.395 | 7.36 ± 1.582 |
 1:5 | 99.39 ± 0.485 | 0.127 ± 0.006 | − 2.5 ± 0.064 | 64.77 ± 0.055 | 8.28 ± 0.004 |
Lipid:polymer mass ratio | Fixed lipid: surfactant (1:0.5) and drug: lipid (1:5) mass ratios | ||||
 1:0.05 | 90.58 ± 0.255 | 0.126 ± 0.004 | − 2.54 ± 0.255 | 55.81 ± 0.448 | 7.38 ± 0.051 |
 1:0.1 | 99.39 ± 0.485 | 0.127 ± 0.006 | − 2.5 ± 0.064 | 64.77 ± 0.055 | 8.28 ± 0.004 |
 1:0.15 | 108.0 ± 0.907 | 0.136 ± 0.009 | − 3.16 ± 0.530 | 72.27 ± 0.280 | 8.86 ± 0.001 |